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Abstract. Liquid extraction surface analysis mass spectrometry (LESA MS) has the
potential to become a useful tool in the spatially-resolved profiling of proteins in
substrates. Here, the approach has been applied to the analysis of thin tissue
sections from human liver. The aim was to determine whether LESA MS was a
suitable approach for the detection of protein biomarkers of nonalcoholic liver disease
(nonalcoholic steatohepatitis, NASH), with a view to the eventual development of
LESA MS for imaging NASH pathology. Two approaches were considered. In the
first, endogenous proteins were extracted from liver tissue sections by LESA, sub-
jected to automated trypsin digestion, and the resulting peptidemixture was analyzed
by liquid chromatography tandem mass spectrometry (LC-MS/MS) (bottom-up
approach). In the second (top-down approach), endogenous proteins were extracted by LESA, and analyzed
intact. Selected protein ions were subjected to collision-induced dissociation (CID) and/or electron transfer
dissociation (ETD) mass spectrometry. The bottom-up approach resulted in the identification of over 500
proteins; however identification of key protein biomarkers, liver fatty acid binding protein (FABP1), and its variant
(Thr→Ala, position 94), was unreliable and irreproducible. Top-down LESA MS analysis of healthy and diseased
liver tissue revealed peaks corresponding to multiple (~15–25) proteins. MS/MS of four of these proteins
identified them as FABP1, its variant, α-hemoglobin, and 10 kDa heat shock protein. The reliable identification
of FABP1 and its variant by top-down LESA MS suggests that the approach may be suitable for imaging NASH
pathology in sections from liver biopsies.
Key words: LESA, Liquid microjunction, Ambient, Bottom-up, Top-down, Proteomics
Received: 28 March 2014/Revised: 10 July 2014/Accepted: 15 July 2014/Published nline: 3 September 2014
Introduction
Nonalcoholic steatohepatitis (NASH) is an inflammatorycondition of the liver that mimics the damage caused by
alcohol without the consumption of large quantities of alcohol.
The disease is characterized by the presence of steatosis and
fibrosis that can lead to cirrhosis. The lobular destruction and
cell loss characteristic of cirrhosis compromise liver function
and ultimately lead to liver failure [1]. Causes of the disease
remain to be fully characterized but both genetic predisposition
and lifestyle choices are important [2]. In common with other
liver diseases, serum biomarkers such as elevated amino trans-
ferases and a glutamyltransferase are found in patients with
NASH, but to date no disease-specific profile of biomarkers
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has been reported. However, changes in the liver fatty acid
binding protein [1, 3–5] show promise. Liver fatty acid binding
protein (FABP1 or L-FABP) is a regulator of hepatic lipid
metabolism. Recent work by Peng et al. [6] has shown that
two single nucleotide polymorphisms in the FABP1 gene are
associated with increased risk of developing non-alcoholic
fatty liver disease. The first results in substitution of threonine
for alanine at position 94 in FABP1, whereas the second is
intronic. Increased risk of disease is linked to the two single
nucleotide polymorphisms both individually and cumulatively;
however, the mechanisms by which these polymorphisms con-
tribute to the disease process are unknown. Recent work by
Huang et al. [7] suggests that the Thr→Ala substitution alters
the structure of FABP1 and the conformational changes that
accompany binding of long chain fatty acids.
In the present work, we seek to determine whether liquid
extraction surface analysis mass spectrometry (LESA MS) of thin
tissue sections from human liver could be applied to the study of
NASH. Specifically, the aim was to determine whether the ap-
proach could be applied for the analysis of protein biomarkers of
the disease, with particular emphasis on FABP1 and its Thr→Ala
variant. Both bottom-up and top-down approaches have been
considered. In the former, endogenous proteinswere extracted from
the tissue and subjected to automated tryspin digestion [8] before
the resulting peptides were analyzed by LC-MS/MS, and in the
latter, endogenous proteins were extracted and analyzed intact [9].
LESA, also known as liquid microjunction surface sam-
pling, has the potential to become a useful tool in mass spec-
trometry imaging of proteins. The technique involves deposi-
tion of a solvent droplet from a pipette tip onto a surface [10–
12]. The solvent droplet maintains contact with both the surface
and the pipette tip for a defined time period (a few seconds)
before being re-aspirated. The resulting sample can either be
directly electrosprayed or subjected to further manipulation
before mass spectrometry analysis. In the present work, auto-
mated LESA was performed.
LESA mass spectrometry of intact proteins was first demon-
strated by Van Berkel and coworkers [13]. They used a contin-
uous flow liquid microjunction system coupled with an ion trap
mass spectrometer to analyze lysozyme protein standard
(14.3 kDa) spotted onto a glass surface. Earlier work from our
laboratory demonstrated that LESAMSwas suitable for the top-
down analysis of proteins from dried blood spots. The approach
was applied to the screening for known hemoglobin variants [14,
15] and to the diagnosis of unknown hemoglobin variants [16]
(~15 kDa) in neonatal samples. A continuous flow version of the
LESA technology has been applied to the analysis of hemoglo-
bin in dried blood spots from sheep [13]. More recently, manual
LESAwas applied to sampling of intact proteins from thin tissue
sections of bovine lens, and murine brain and kidney [9].
In order for LESA to be coupled with bottom-up proteo-
mics, a proteolytic digestion step needs to be introduced into
the workflow. Two approaches exist; in the first, intact proteins
are extracted by LESA prior to digestion [8], and in the second,
in-situ digestion is performed prior to liquid microjunction
extraction [17, 18]. The first approach was applied to the
analysis of dried blood spots, identifying over 100 proteins,
and made use of the Advion TriVersa NanoMate (Advion
Biosciences, Ithaca, NY, USA) for both the liquid
microjunction extraction and the automated digestion proce-
dure. A key challenge for the latter approach is preventing
evaporation of the trypsin solution. In-situ digestion was dem-
onstrated for protein arrays (cytochrome c, myglobin, and
bovine serum albumin) printed on a biomaterial substrate com-
monly used for cell culture [19]. Quanico et al. [17] applied the
in-situ digestion approach, via repeated deposition of trypsin
solution, to the analysis of thin tissue sections from frozen rat
brain. The approach was subsequently applied to formalin-
fixed and paraffin-embedded tissue sections from fallopian
tube cancer biopsies [18].
Here, we apply LESA coupled with high resolution MS and
MS/MS to survey proteins in sections of human liver. A
bottom-up proteomics approach in which intact endogenous
proteins are extracted by LESA prior to automated trypsin
analysis is compared with a top-down approach in which the
proteins are extracted and directly introduced into the mass
spectrometer. The bottom-up approach identifiedmore proteins
than the top-down approach. Nevertheless, bottom-up identifi-
cation of FABP1 and its variant is irreproducible, whereas the
top-down approach reliably identified this potential biomarker
of nonalcoholic liver disease. The results suggest that top-down
LESA MS may be a suitable approach for imaging NASH
pathology in sections from liver biopsies.
Methods
Sample Preparation
The work was approved by the NHS Walsall Local Research
Ethics Committee (98/CA5192). All patient liver tissue was
collected at The Queen Elizabeth Hospital in Birminghamwith
written informed patient consent. Healthy liver tissue was
collected from donor material surplus to transplantation re-
quirements or from resection margin specimens. Diseased liver
specimens were collected upon transplantation surgery. All
samples were rapidly processed and snap-frozen in liquid ni-
trogen prior to storage at –80°C.
Sections of normal human liver tissue of area approximately
1.5 cm2 were obtained at a thickness of 10 μm using a CM1810
cryostat (Leica Microsystems, Wetzlar, Germany) and thaw
mounted onto glass slides.
Bottom-Up LESA Mass Spectrometry of Human
Liver Tissue Sections
Intact proteins were extracted from healthy human tissue via
automated LESA. Samples were mounted onto a 96-well mi-
crotiter plate (Thermo Scientific, Loughbrough, UK) and
placed in the TriVersa NanoMate nanoelectrospray device.
Three of the sample wells contained extraction solvents: one
contained 50 mM ammonium bicarbonate, one contained 50%
methanol, and one contained 70% methanol. A fourth well
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contained 0.1 μg/μL trypsin (Trypsin Gold; Promega, South-
ampton, UK) in 50 mM acetic acid. Surface sampling of the
thin tissue section and trypsin digestion was performed using
the advanced user interface (AUI) feature of the ChipSoft
Manager software, which controls the Triversa Nanomate.
Following LESA extraction and digestion, each sample was
analyzed in duplicate by LC-MS/MS.
Liquid Extraction Surface Analysis Two μL of extraction
solvent was aspirated from the solvent well. The robotic
arm relocated to a position above the tissue section and
descended to a height of approximately 0.6 mm above the
surface. One μL of the solution was dispensed onto the
tissue section to form a liquid microjunction. The liquid
microjunction was maintained between the probe tip and
the surface for 1 s; then 1.3 μL were reaspirated into the
pipette tip. The dispense-reaspiration cycle was repeated
three times before finally dispensing into a clean well in
the microtiter plate. The experiment was conducted using
three extraction solutions: (1) 50% methanol, (2) 70%
methanol, and (3) 50 mM NH4HCO3. After extraction,
the 50% and 70% methanol solutions were left for
30 min until dry to remove the organic content, and the
sample was resuspended in 10 μL 50 mM NH4HCO3,
using one mix cycle (repeat dispense/reaspiration) to pro-
mote resuspension. For each of the samples, 4.5 μL of
trypsin solution was aspirated from the tryspin-containing
well and dispensed into the sample well. The solutions
were mixed by a single mix cycle (repeat dispense/
reaspiration). The samples were incubated at 37°C for
1 h by using the temperature control unit of the TriVersa
NanoMate. At 30 min and 1 h into the incubation, 7 μL of
50 mM NH4HCO3 was aspirated from the solvent well and
added to the sample well in order to account for evapora-
tion. The final volume was approximately 10 μL.
LC MS/MS The microtiter plate was transferred to the
HPLC autosampler (Ultimate 3000; Dionex Thermo Fisher
Scientific, Loughborough, UK), which is coupled to an
Orbitrap Velos ETD mass spectrometer (Thermo Fisher
Scientific, Bremen, Germany) via the TriVersa NanoMate.
The proteolytic digests were each analyzed in duplicate by
LC-MS/MS. Five μL aliquots were injected onto a Pepmap
100, C18 100 μm trap (Thermo Fisher Scientific). The trap
was treated with a 5 min wash cycle with 0.1% formic acid
prior to injection onto the analytical column (Pepmap 100
reversed phase C18 75 μm, 3 μm, 100 Å; Thermo Fisher
Scientific). Peptides were separated using a 30 min 3.2%
to 44% ACN (J. T. Baker, Deventer, The Netherlands)
gradient at a flow rate of 0.35 μL/min.
Samples eluted into the mass spectrometer via the Triversa
Nanomate chip-based nanoelectrospray device. Ionization volt-
age was 1.4 kV, gas pressure was 0.3 psi, and capillary tem-
perature was 250°C. Mass spectrometry analysis was per-
formed via a ‘top 7’ method in which a survey scan was
followed by MS/MS of the seven most abundant precursor
ions. Survey scans were acquired in the Orbitrap with a m/z
range 380–1800, an automatic gain control (AGC) target of 1 ×
106 charges, a maximum fill time of 1 s, and a resolution of
60,000 at m/z 400. CID was performed in the linear ion trap
(AGC target: 30,000 charges) with helium gas and a normal-
ized collision energy of 35%. The width of the precursor
isolation window was 2 Th and only multiply charged precur-
sor ions were subjected to CID. The mass exclusion window
was m/z ±0.05 and the exclusion list was set to 500. Dynamic
exclusion was applied for 60 s.
MS/MS data were searched against the SwissProt human
database (downloaded November 2012), composed of 20,203
sequences, supplemented with the FABP1 variant, using the
Mascot and Sequest algorithms in Proteome Discoverer 1.4.
Two sets of parameters were applied. In one set, the parameters
were: precursor ion mass accuracy 10 ppm, fragment mass
tolerance 0.8 Da, methionine oxidation was allowed as a dy-
namic modification, up to two missed cleavages in the diges-
tion. In the second set, three missed cleavages were allowed,
with all other parameters the same as before. Data were filtered
to a false discovery rate of 1% by including only high confi-
dence peptides. The protein grouping algorithm was applied,
which grouped all non-unique peptides to the highest scoring
protein.
Top-Down LESA Mass Spectrometry of Human
Liver Tissue Sections
Sections of human liver thaw-mounted onto glass slides
were washed in a solution of 80% ethanol. The slides were
mounted onto the Advion LESA universal plate adapter
and an image of the tissue section was acquired using an
Epson Perfection V300 photo scanner. The LESA Points
software (Advion) was used to select the precise location of
the tissue section to be sampled. The universal plate adapter
was placed into the TriVersa NanoMate. Extraction/
electrospray solution comprising 40% acetonitrile + 1% formic
acid was placed in the solvent well.
Liquid Extraction Surface Analysis Two μL of 40% acetoni-
trile + 1% formic acid was aspirated from the solvent well. The
robotic arm relocated to a position above the tissue section and
descended to a height of approximately 1 mm above the
surface. One μL of the solution was dispensed onto the tissue
section to form a liquid microjunction. The liquid
microjunction was maintained between the probe tip and the
surface for 10 s. Then, 1.3 μL was reaspirated into the pipette
tip. The dispense/reaspirate cycle was repeated three times. The
sample was introduced into the mass spectrometer via the
TriVersa NanoMate, at a flow rate of ~150 nL/min, with gas
pressure 1.3 psi, a tip voltage of 1.7 kV, and a capillary
temperature of 250°C. All spectra were collected in the
Orbitrap at a resolution of 100,000 at m/z 400. Full scan mass
spectra (m/z 500–2000) were collected for 3 min. AGC target
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was 1 × 106 charges with a maximum injection time of 2 s. CID
was performed in the ion trap at a normalized collision energy
of 30% and the fragments detected in the Orbitrap (m/z 300–
2000). The isolation width was 3 Th. AGC target was 1 × 106
charges with a maximum injection time of 2 s. Each CID MS/
MS scan comprised of 20 co-added microscans. Data were
recorded for 10 min (~10 scans). ETD was performed in the
ion trap and the fragments detected in the Orbitrap. The isola-
tion width was 3 Th. AGC target was 1 × 106 charges with a
maximum injection time of 1 s. ETD activation time was
20 ms. Each ETD scan comprised of 20 co-added microscans.
Data were recorded for 6 min (~9 scans).
All mass spectra were deconvoluted using Xcalibur’s Xtract
function, in order to obtain monoisotopic masses.Mass spectra
were processed with a signal to noise ratio threshold of three.
The processed fragment ion list was submitted to Prosight PTM
2.0 (https://prosightptm2.northwestern.edu) using the simple
human database, allowing all modifications, and peak accuracy
of 10 ppm. Identity was confirmed by manual analysis using
Protein Prospector (http://prospector.ucsf.edu/prospector/
mshome.htm).
Results and Discussion
Bottom-Up LESA Mass Spectrometry of Human
Liver Tissue Sections
Intact proteins were extracted from healthy human liver tissue
via automated direct surface sampling by LESA and subjected
to automated trypsin digestion using the method described by
Martin et al. [8]. In that work, Martin et al. found that 1 h was
the optimum digestion time. Three extraction solvents were
considered: 70% (v/v) methanol, 50% (v/v) methanol, and
50 mM ammonium bicarbonate. The three extraction solvents
were applied for LESA of three serial sections from a tumor
resection margin. For each extraction solvent composition, two
technical replicates were performed. Two searches of the data
against the protein database were performed in order to deter-
mine the effect of the short digestion time. In the first, two
missed trypsin cleavages were allowed, and in the second, three
missed cleavages were allowed. When two missed cleavages
were allowed, a total of 475 non-redundant proteins were
detected: 428 proteins were detected following the ammonium
bicarbonate extraction; 200 were detected following the 50%
methanol extraction, and 99 were detected following the 70%
methanol extraction. When three missed cleavages were
allowed, 549 non-redundant proteins were detected: 464 pro-
teins were detected following the ammonium bicarbonate ex-
traction; 214 were detected following the 50% methanol ex-
traction, and 116 were detected following the 70% methanol
extraction. See Figure 1a. Proteins identified are detailed in
Supplementary File 1. Single peptide protein identifications are
presented in Supplementary File 2. Increasing the organic
solvent content of the extraction solution resulted in fewer
identifications, and this is perhaps not surprising. This
observation has relevance to the top-down analysis and is
discussed further below.
The bottom-up protocol used here was originally developed
for the analysis of dried blood spots [8]. The number of proteins
identified from the liver tissue is over 4-fold greater than were
detected in dried blood spots, despite using a much smaller
volume for the liquid microjunction (1 μL versus 6 μL). This
observation is perhaps expected given that the liver is a center
for metabolism within the body and has an abundance of
proteins and enzymes [20]. Blood is a small component of liver
tissue and abundant proteins such as alpha and beta hemoglo-
bin chains were also detected. It is possible that the numbers of
identified proteins could be increased, either by pooling ex-
tracted samples or by performing on-tissue digestion [17]. The
latter cannot be achieved, at least in our hands, using the
TriVersa NanoMate because of the problem of evaporation of
the trypsin solution.
Three known liver diseasemarkerswere identified in each of the
three extractions: the liver fatty acid binding protein (FABP1) (MW
15.1 kDa) [6], gamma-glutamyltransferase (MW 77.3 kDa) [18],
and aspartate amino transferase [3]. There are two forms of aspar-
tate amino transferase, one found in the mitochondria (MW
47.5 kDa) and the other found in the cytoplasm (MW 46.2 kDa).
The homology between the two sequences is 68% (as calculated by
BLASThttp://blast.ncbi.nlm.nih.gov/Blast.cgi). Both proteinswere
(a)
(b)
Figure 1. (a) Total number of proteins identified from healthy
human liver tissue using a bottom-up approach following LESA
extraction using solvents comprising 50 mM NH4(HCO3), 70%
methanol, and 50%methanol. (b) Sequence coverage obtained
for FABP1 following 50 mM NH4(HCO3) extraction, automated
tryptic digestion, and LC MS/MS from two technical replicates
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identified by unique peptides in the current dataset. Proteins
gamma-glutamyltransferase and the mitochondrial aspartate amino
transferase were detected with greatest sequence coverages
(32.90% and 48.37% respectively) following the ammonium
bicarbonate extraction. The greatest sequence coverage
(52.52%) for cytoplasmic aspartate amino transferasewas observed
following extraction with 50% methanol.
FABP1 was detected in each of the six experiments with
sequence coverage ranging between 53% and 57% (see Sup-
plementary Figure 1). Figure 1b shows the sequence coverages
(a)
(b)
Figure 2. CID mass spectra of +3 ions of tryptic peptides [TVVQLEGDNKLVTTFK] and [TVVQLEGDNKLVTAFK] from FABP1 and
FABP1TA identified following LESA extraction with 50 mM NH4(HCO3) extraction followed by trypsin digestion and LC-MS/MS
Figure 3. Full scan mass spectrum obtained following LESA MS analysis of healthy human liver tissue. Inset: enlarged region (m/z
750–950). Labeled peaks are: FABP1 (blue circle), FABP1TA (green triangle), α-hemoglobin (red square), and 10 kDa heat shock
protein (yellow star). Proteins were identified using CID and/or ETD
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obtained for the two replicates obtained following extraction
with ammonium bicarbonate solution. As described above,
FABP1 and its variant implicated in NASH differ by a single
amino acid residue (i.e., Thr→Ala at position 94). The tryptic
peptide containing residue 94, that is [91-96], was not observed
in any of the analyses. (It is possible that an SRM approach
may identify the relevant peptide more reproducibly; however,
the Orbitrap instrument used in this work is not suited to such
an approach). One of the analyses following extraction with
ammonium bicarbonate resulted in the identification of the
missed-cleavage tryptic peptide [81-96] (m/zmeas 1791.9931,
m/zcalc 1791.9851, Δ 4.9 ppm) from FABP1. The CID mass
spectrum obtained from the [M+3H]3+ peptide ions is shown in
Figure 2a. The fragmentation sequence coverage for the pep-
tide is poor with no cleavage around the potential substitution
site. Clearly, as the variant is the result of a single amino acid
substitution and the sequences of FAPB1 and its variant are
virtually identical, with the exception of peptide [81-96], the
peptides assigned to FABP1 in the database search could also
have originated from the variant. The human SwissProt data-
base against which the database was searched was supplement-
ed with the FABP1 variant (hereafter referred to as FABP1TA).
The peptide [90-96] from FABP1TA was not identified in any
of the analyses; however, the missed-cleavage peptide [81-96]
was identified in one of the ammonium bicarbonate extraction
replicates (m/zmeas 1761.9831, m/zcalc 1761.9745, Δ 4.5 ppm).
The CID spectrum is shown in Figure 2b. Again, fragmentation
sequence coverage is poor and no fragmentation was observed
adjacent to the site of substitution. It should be noted that top-
down analysis of this tissue sample (see below) revealed the
presence of the variant.
Untargeted Identification of Intact Proteins
in Human Liver
Four samples were investigated by top-down LESA mass
spectrometry: two NASH samples and two healthy (non-
diseased) samples. The non-diseased samples were from (1) a
tumor resection margin, and (2) a donor liver not suitable for
transplantation.
Liver sections were thaw-mounted onto glass slides and
dipped into 80% (v/v) ethanol prior to LESA analysis. This
washing step removes lipids and improves protein signal in the
mass spectra. The sections were subjected to LESA using
extraction solvent comprising 40% (v/v) acetonitrile + 1%
formic acid, and the resulting samples introduced directly, via
electrospray ionization, into the mass spectrometer.
Deconvolution of the resulting mass spectra using the Xtract
program suggested that the spectra comprised peaks corre-
sponding to up to 16 proteins in healthy tissue and up to 25
proteins in NASH tissue, with molecular weights ranging be-
tween 3000 and 20,000 Da. The results from the bottom-up
analyses described above suggest that a greater number of
proteins are extracted using ammonium bicarbonate solution;
however, the top-down workflow requires that the extraction
solution must also be suitable for electrospray ionization. If the
extraction and electrospray steps were decoupled, it may be
possible to increase the number of top-down identifications.
Figure 3 shows the mass spectrum obtained from a healthy
liver sample. Four abundant protein ions were selected for
tandem mass spectrometry. Note that the nature of the proteins
was not known a priori. Ions at m/z 946.38 (+16 charge state)
(a)
(b)
(c)
Figure 4. CID mass spectra obtained from +15 ions of (a)
FABP1 and (b) FABPTA following LESA of human liver sections.
Insets: observed sequence coverage: b/y ions are shown in
black and a ions in red. (c) Enlarged region showing m/z 1172–
1193
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were selected for collision induced dissociation MS/MS. The
data were searched against the simple human database in
Prosight PTM 2.0, and the protein was identified as the alpha
chain of hemoglobin (MWmeas 15117.9167, MWcalc
15117.8924, Δ 1.6 ppm). Fragments identified are detailed in
Supplementary Table 1. The protein sequence coverage fol-
lowing CID was 31%. Ions of the same m/z (m/z 946.38)
observed in the analysis of NASH tissue were selected and
subjected to electron transfer dissociation MS/MS. Again, the
protein was identified as α-hemoglobin. The ETD protein
sequence coverage was 13% and the fragments observed are
detailed in Supplementary Table 2. The combined sequence
coverage from the two analyses was 42%.
Ions at m/z 775.42 (+14 charge state) observed in the
mass spectrum from healthy tissue were selected and
subjected to both CID MS/MS and ETD MS/MS and
the data searched against the simple human database in
Prosight PTM 2.0. (A peak at this m/z was also observed
in NASH tissue however its abundance was insufficient
for MS/MS). The protein was identified as mitochondrial
10 kDa heat shock protein (MWmeas 10836.8056, MWcalc
10836.8485, Δ 3.96 ppm). The protein sequence coverage
was 25% (CID) and 21% (ETD), giving an overall cove-
rage of 39%. Details of the fragments observed are given
in Supplementary Tables 3 and 4.
The ions atm/z 1084.80 and 1087.04 (both +15 charge state)
were each selected for CID MS/MS. The two species were
identified as FABP1 (MWmeas 14111.4161, MWcalc
14111.3892, Δ 1.9 ppm) and the variant FABP1TA (MWmeas
14081.3600, MWcalc 14081.3687, Δ 0.6 ppm). Both proteins
were detected with the initiator methionine removed and acet-
ylation of the N-terminus. Therefore, the 92nd and 93rd amino
acids in each chain are TT and TA, respectively. The CID
sequence coverage obtained was 47% for FABP1 and 33%
for the variant FABP1TA. Fragments observed are detailed in
Supplementary Tables 5 and 6. The site of substitution can be
confirmed. The CID MS/MS spectra from both FABP1 and
FABP1TA are shown in Figure 4.
Ions of m/z 942.23 and 940.29 (+16 charge state) (corre-
sponding to FABP1 (MWmeas 14111.3943, MWcalc
14111.3892, Δ 2.4 ppm) and FABP1TA (MWmeas
14081.2845, MWcalc 14081.3687, Δ 6.0 ppm) from a NASH
sample were subjected to ETD MS/MS. The sequence cover-
ages obtained were 38% and 29%, see Supplementary Tables 7
and 8. The ETDMS/MS spectra of FABP1 and FABP1TA from
NASH tissue are shown in Figure 5.
Figure 6 shows expanded m/z regions containing the +16
charge state of FABP1 and FABP1TA of the mass spectra
obtained for the four samples analyzed. Figure 6a and b show
the mass spectra from healthy (non-diseased) tissue. In one
sample, only FABP1 is observed, whereas in the other both
FABP1 and the variant are observed. Figure 6c and d show the
mass spectra from NASH tissue. Similarly, one sample con-
tains the variant alone, whereas the other reveals the presence
of both FABP1 and FABP1TA. As described above, it has been
demonstrated recently that individuals with FABPTA have an
increased risk of developing NASH [6]. In addition, it was
shown that another polymorphism compounds that risk. The
observation of the variant in non-diseased tissue could be
explained by the risk associated with FABPTA being attenuated
by other factors. It is worth noting, however, that the sample
containing both FAPB1 and the variant was from a tumor
resection margin, whereas the sample containing FAPB1
alone was from a liver rejected for transplant because of
the presence of a small lesion. The non-diseased samples
are also characterized by reduced signals for α-hemoglobin.
In the case of the liver rejected for transplant (Figure 6a), the
organ was perfused with buffer (i.e., blood was removed)
following removal from the donor. In the case of the tumor
resection margin (Figure 6b), it is likely that the surgical
procedure resulted in local hemolysis and reduced blood
supply.
(a)
(b)
Figure 5. ETD mass spectra obtained from +16 ions of (a)
FABP1 and (b) FABPTA following LESA of NASH human liver
sections. Insets: observed sequence coverage: c/z ions are
shown in red, a/y ions in black
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Conclusion
We have shown that LESA mass spectrometry is a suitable tool
for the investigation of proteins in healthy and diseased human
liver tissue. Bottom-up analysis results in identification of far
greater numbers of proteins than does top-down analysis. It may
be possible to increase the number of top-down identifications
by introducing a liquid chromatography step or by decoupling
the extraction step from the electrospray ionization step thereby
enabling the use of different solvent systems in each case.
Given that the protein FABP1 and its variant FABPTA are
implicated in nonalcoholic liver disease, it is particularly impor-
tant to be able to distinguish between the two forms. The bottom-
up approach, although confidently identifying the FABP1 protein
in all cases, does not reliably and reproducibly detect the peptide
containing the site of amino acid substitution. The results suggest
that the bottom-up approach is not suitable for the spatially
resolved profiling of NASH tissue sections. (It should be noted,
however, that the timescale of the trypsin proteolysis step best-
suited for efficient, integrated LESA-based analysis is 1 h. An
overnight digestion may yield better sequence coverage, as might
alternative proteases). Conversely, the top-down approach easily
distinguishes FABP1 and FABPTA. Peaks corresponding to the
two species are clearly discerned in the mass spectra and are, in
fact, some of the most abundant. MS/MS of the intact proteins
(either CID or ETD) allows the nature of the proteins to be
confirmed, including the site of substitution. Further work will
focus on validation of the approach on larger numbers of sam-
ples, together with development of LESA-based top-down mass
spectrometry for spatially-resolved profiling of NASH tissue.
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Figure 6. Expanded m/z regions from the full scan mass spectra obtained following LESA MS analysis of two healthy human liver
sections (a) and (b), and two NASH human liver sections (c) and (d). Labeled peaks are FABP1 (+16 charge state) (blue circle),
FABP1TA (+16 charge state) (green triangle), and α-Hb (+16 charge state) (red square)
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